These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6862049)

  • 1. Alloreactive cytotoxic anti-H-2 antibodies in sera of the syngeneically immunized C57BL/10ScSnPh, BALB/cJPh, and B10.A/SnPh mice.
    Capková J; Hasek M; Kousalová M; Holán V; Boubelík M
    Folia Biol (Praha); 1983; 29(2):200-8. PubMed ID: 6862049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the possibility of induction of anti-H-2 alloreactive cytotoxic antibodies by syngeneic immunization.
    Opolski A; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1984; 32(5):621-30. PubMed ID: 6085470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
    Sensi ML; Parenza M; Parmiani G
    J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
    Tremblay N; Fontaine P; Perreault C
    Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Production of heterologous antibodies to T-killers of mice immunized against H-2 antigens].
    Egorova SG; Gritsman AIu; Brondz BD
    Biull Eksp Biol Med; 1980 Jul; 89(7):62-4. PubMed ID: 6157432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclical changes in susceptibility of a myeloma tumor (LPC-1) to immune destruction. I. Changes in reactivity with cytotoxic T lymphocytes and anti-H-2d sera.
    Celis E; Hale AH; Russell JH; Eisen HN
    J Immunol; 1979 Mar; 122(3):954-8. PubMed ID: 312828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A syngeneic anti tumor serum recognizing a complex H-2 alloantigen.
    Garrido F; Perez M; Torres MD; Garcia-Olivares E; Ivanyi P; Schirrmacher V
    Immunobiology; 1979 Aug; 156(1-2):110-20. PubMed ID: 540966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytolytic activity of murine CD4+ T cell clones correlates with IFN-gamma production in mouse strains having a BALB/c background.
    McKisic MD; Lancki DW; Fitch FW
    J Immunol; 1993 May; 150(9):3793-805. PubMed ID: 8097225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selective inactivation of specific T-suppressors immune to H-2 complex antigens and prevention of their generation in vivo by antisuppressor xenogenic antibodies].
    Abronina IF; Brondz BD; Suslov AP; Zaitseva MB; Karaulov AV
    Mol Biol (Mosk); 1981; 15(5):1131-43. PubMed ID: 6457978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of anti-H-2 class I antibodies induced by syngeneic immunization with Sendai virus-treated cells is regulated by the mouse MHC and viral antigens. No evidence for MHC-restricted virus-specific antibodies.
    Kievits F; van Bleek GM; Boerenkamp WJ; Pla M; Ivanyi P
    J Immunogenet; 1989 Feb; 16(1):3-17. PubMed ID: 2550555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of anti-H-2K and H-2D alloantibodies in enhancement and acute antibody-mediated rejection of mouse skin allografts.
    de Waal RM; Capel PJ; Koene RA
    J Immunol; 1980 Feb; 124(2):719-23. PubMed ID: 6985936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naturally occurring leukemia viruses in H-2 congenic C57BL mice. II. Antibody response to viral envelope antigens.
    Vlug A; Melief CJ; de Bruyne C; Schoenmakers H; Molenaar JL
    J Natl Cancer Inst; 1980 May; 64(5):1191-8. PubMed ID: 6245302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo.
    Schirmbeck R; Melber K; Kuhröber A; Janowicz ZA; Reimann J
    J Immunol; 1994 Feb; 152(3):1110-9. PubMed ID: 8301120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of the anti-tumour immune response by suppressor gene products of lymphoid cells.
    De Giorgi L; Matossian-Rogers A; Festenstein H
    Immunology; 1979 Apr; 36(4):711-8. PubMed ID: 108205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ia versus K/D antigens in immunological enhancement of tumour allografts. II. Studies with alloimmune sera prepared in recombinant strains.
    Duc HT; Kinsky RG; Voisin GA
    Ann Immunol (Paris); 1979; 130C(3):461-74. PubMed ID: 475347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between foreign H-2-like antigens on MCG4 sarcoma and the in vivo rejection of this tumor by syngeneic and semisyngeneic mice.
    García-Olivares E; Torres MD; Gutiérrez F; Osorio C
    Rev Esp Fisiol; 1982 Mar; 38(1):9-12. PubMed ID: 7100610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Specifics anti-tumor immunity induced by gene immunization with ectopic hCGbeta encoding gene].
    Wang LX; Wu J; Guan QD; Xiong SD
    Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):316-9. PubMed ID: 12921555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Induction of T-cells--producers of macrophage migration inhibitory factors by mutant H-2 antigens in vivo].
    Kharkevich DD; Suslov AP; Blandova ZK
    Biull Eksp Biol Med; 1984 Apr; 97(4):443-5. PubMed ID: 6372888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elicitation of anti-H-2 cytotoxic T lymphocytes with antigen-modified H-2 negative stimulator cells.
    Hale AH; Ruebush MJ; Harris DT; McGee MP
    J Immunol; 1981 Apr; 126(4):1485-8. PubMed ID: 6970778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new minor histocompatibility locus linked to H-3.
    Click RE; Schneider D; Roopenian DC
    J Immunol; 1981 Jun; 126(6):2378-81. PubMed ID: 7229381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.